 Safety effects plus zidovudine asymptomatic individuals human immunodeficiency virus safety continuous i.v conjunction zidovudine ZDV asymptomatic patients human immunodeficiency virus Clinical immunologic viral parameters phase I/II trial dose escalation crossover arms Daily doses presence ZDV increases antigenemia Significant transient increases cells infusion doses natural lymphokine-activated killer activity doses hypodense eosinophils soluble receptors patients available long-term months baseline months counts baseline mean increase patients significant patients negative serum start therapy none antigenemic long-term follow-up